endometrial cancer
Context Therapeutics Begins Phase I Trial of Bispecific Antibody in CLDN6-Positive Tumors
The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.
Repare Therapeutics Shuffles Pipeline, Pauses Some Programs Pending Partnership
The firm will pause development of lunresertib and camonsertib while focusing on development of two newer programs.
Ideaya Biosciences to Develop KAT6/7 Inhibitor in 8p11-Amplified Breast, Lung Cancers
The firm plans to file an investigational new drug application to study IDE251 in clinical trials in 2025.
Merck's Keytruda Added to Adjuvant Chemo Benefits Newly Diagnosed Endometrial Cancer Subpopulation
Premium
The combination did not benefit a biomarker unselected population, but those with mismatch repair-deficient tumors had extended disease-free survival.
The firm recently started treating patients in a Phase I trial of its pol theta helicase inhibitor and filed an IND for its Werner helicase-targeted drug candidate.
Feb 6, 2024
Aug 23, 2023